Gregory Michael Lubiniecki, MD
Lung Cancer, Mesothelioma
American Board of Internal Medicine;
Board Eligible for internal medicine, medical oncology, hematology
Having witnessed family members' experiences with cancer when I was younger sparked my interest in medicine, and, specifically, oncology. After completing my training, I worked for the Clinical Practices of the University of Pennsylvania as a medical oncologist. In 2009, I joined Fox Chase Cancer Center. I specialize in patients with lung cancer and mesothelioma.
Because we are all unique and cancer is a challenging diagnosis, I believe that it is important to address a patient's individual needs. Communication is very important between the doctor and patient, as well as among the members of a patient's health care team. A multi-disciplinary approach involving various subspecialties of cancer doctors and health care team members is a great means of caring for patients with cancer. Fox Chase Cancer Center provides such care, and I feel privileged to participate in this style of health care delivery. I strive to provide current treatments that are in keeping with a patient's goals and that have been demonstrated to have the best chance of success at treating patients with minimal side effects.
Dr. Lubiniecki has a clinic at Fox Chase Cancer Center on Friday mornings.
MD Johns Hopkins University, Baltimore MD, 1998.
Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN, 2001
Fellow, Hematology/Oncology, University of Pennsylvania, 2004.
Honors and Awards
Award for Excellence, Merck & Co., Inc., 2008;
Who's Who of Emerging Leaders, 2007;
Who's Who in Medicine and Healthcare (5th and 6th editions), 2004-2007;
Who's Who in Science and Engineering (7th and 9th editions), 2003-2004, 2006-2007;
ASCO Merit Award, 2003;
Who's Who in America (56th-61st editions), 2002-2007
American College of Physicians - American Society of Internal Medicine ;
American Medical Association;
American Society of Clinical Oncology ;
American Society of Hematology;
International Association for the Study of Lung Cancer;
Pennsylvania Medical Society
Lung Cancer, Mesothelioma, Novel Therapies